Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
J Dermatolog TreatMay 21, 2026 (epub)
Clinical ResearchDermatology
Emma Guttman-Yassky, Thomas Bieber, Kenji Kabashima et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase III randomized controlled trial evaluated the sustained off-treatment disease control in patients with moderate-to-severe atopic dermatitis after 12 weeks of abrocitinib 200 mg. Following randomization to placebo, abrocitinib 100 mg, or abrocitinib 200 mg for 40 weeks, 21.3% of patients in the placebo group experienced no off-treatment flares, indicating potential disease remission.
Key findings
- 21.3% of patients in the placebo arm had no off-treatment flares.
- The no-flare group had mean EASI, IGA, PP-NRS, and DLQI scores of 2.9, 1.0, 2.6, and 3.5, respectively.
- Patients achieved clear/mild AD at week 52 after 12 weeks of abrocitinib treatment.
Why it matters
Understanding the potential for sustained off-treatment disease control in atopic dermatitis can guide clinicians in managing long-term treatment strategies and patient expectations regarding remission.